The Valley Hospital
Welcome,         Profile    Billing    Logout  
 61 Trials 
117 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Dragnev, Konstantin H
ASTRIDE, NCT05468489: To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Recruiting
3
200
US
Serplulimab + chemotherapy (carboplatin-etoposide), Atezolizumab + chemotherapy (carboplatin-etoposide)
Shanghai Henlius Biotech
Extensive Stage Small Cell Lung Cancer
04/25
12/25
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
NCT05578326: Study of Trilaciclib and Lurbinectidin

Recruiting
2
30
US
Trilaciclib, Lurbinectedin
UNC Lineberger Comprehensive Cancer Center, G1 Therapeutics, Inc.
Lung Cancer, Small-cell Lung Cancer
12/25
12/27
A071401, NCT02523014: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas

Recruiting
2
124
US
Vismodegib, GDC-0449, FAK Inhibitor GSK2256098, Capivasertib, AZD5363, Abemaciclib
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation
Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
01/26
01/28
NCT06362369: A Study of Oral 7HP349 (Alintegimod) in Combination with Ipilimumab Followed by Nivolumab Monotherapy

Recruiting
1/2
126
US
Alintegimod, 7HP349, Ipilimumab, Yervoy, Nivolumab, Opdivo
7 Hills Pharma, LLC
Advanced Cancer, Advanced Solid Tumor, Melanoma, Metastasis, Pleural Mesothelioma, Renal Cell Carcinoma, MSI-High, Mismatch Repair Deficiency, Colorectal Cancer, Hepatocellular Carcinoma, Hepatocellular Cancer, Renal Cell Cancer, Kidney Cancer, Skin Cancer, Non Small Cell Lung Cancer, NSCLC, Anaplastic Lymphoma Kinase Genomic Tumor Aberrations, ALK Genomic Tumor Aberrations
12/27
12/28
MT-6402-001, NCT04795713: Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

Terminated
1
64
US
MT-6402
Molecular Templates, Inc.
Advanced Solid Tumor, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
10/24
10/24
NCT05948865: A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors

Recruiting
1
102
Canada, US
CPO301, SYS6010
Conjupro Biotherapeutics, Inc.
Cancer, Cancer, Lung
06/25
12/25
Bernstein, Jonathan A
CALM-CSU, NCT06077773: Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria

Recruiting
2
154
Europe, Canada, US
Oral EP262, Placebo
Escient Pharmaceuticals, Inc
Chronic Spontaneous Urticaria
06/25
07/25
HAErmony-1, NCT05121376 / 2021-003603-18: A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema

Active, not recruiting
1/2
44
Europe, US, RoW
Dose 1 of BMN 331, Dose 2 of BMN 331, Dose 3 of BMN 331, Dose 4 of BMN 331, Dose 5 of BMN 331, Dose 6 of BMN 331, Dose 7 of BMN 331
BioMarin Pharmaceutical, BioMarin Pharmaceutical Inc.
Hereditary Angioedema, HAE
11/28
11/28
CALM-CIndU, NCT06050928: Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria

Completed
1
33
Europe, Canada, US
Oral EP262
Escient Pharmaceuticals, Inc
Chronic Inducible Urticaria
10/24
10/24
NCT04583007: Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults

No Longer Available
N/A
Europe, Canada, US
Lanadelumab 150 mg, TAK-743, SHP643, DX-2930, Lanadelumab 300 mg
Shire, Takeda Development Center Americas, Inc.
Hereditary Angioedema (HAE), Angioedema
 
 
Lee, Jin Soo
NCT06113198 / 2023-000764-58: A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of Age

Recruiting
4
50
RoW
rMenB+OMV NZ
GlaxoSmithKline, GlaxoSmithKline Biologicals SA
Meningitis, Meningococcal
04/26
09/26
Aladdin, NCT04618640: To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 Years

Recruiting
3
249
RoW
DTaP-IPV combination vaccine
Boryung Biopharma Co., Ltd.
Diphtheria, Tetanus, Pertussis, Poliomyelitis
12/20
07/21
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26
NCT06087640: A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age

Recruiting
3
35800
Europe, RoW
aQIV or aTIV, Fluad Tetra/Quadrivalent or Fluad, QIV or TIV
Seqirus
Influenza, Human
11/26
12/26
NCT06346184: A Study to Evaluate the Pharmacokinetics and Safety Between HCP2303 and Co-administration of Each Component in Healthy Volunteers

Completed
1
37
RoW
HCP2303, RLD2302, RLD2102
Hanmi Pharmaceutical Company Limited
Healthy
06/24
06/24
HM-EMMA-102, NCT06357910: A Study to Evaluate the Pharmacokinetics and Safety Between HCP2303 and Co-administration of Each Component in Healthy Volunteers Under Fed Conditions

Completed
1
34
RoW
HCP2303, RLD2302, RLD2102
Hanmi Pharmaceutical Company Limited
Healthy
07/24
07/24
NCT06518122: A Study to Evaluate the Drug-drug Interaction and Safety Between HCP1306, RLD2302 and RLD2102 in Healthy Volunteers

Not yet recruiting
1
60
RoW
HCP1306, RLD2302, RLD2102
Hanmi Pharmaceutical Company Limited
Healthy
01/25
01/25
Grau, Juan J
FLORA-4, NCT04498117 / 2020-002270-26: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Active, not recruiting
3
615
Europe, Canada, US, RoW
Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo
CanariaBio Inc., Gynecologic Oncology Group, Iqvia Pty Ltd
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms
09/25
08/27
Mittal, Suneet
PUFA, NCT00841451: Pulmonary Vein Isolation Outcomes With Fish Oils

No Longer Available
N/A
US
Lovaza (Fish Oils), Lovaza NDA021654, Omacor NDA021853
St. Luke's-Roosevelt Hospital Center, GlaxoSmithKline
Atrial Fibrillation
 
 
FROZEN-AF, NCT04133168: Boston Scientific's Cryoballoon in the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation

Completed
N/A
458
Europe, Canada, US, RoW
Boston Scientific Cardiac Cryoablation System
Boston Scientific Corporation
Paroxysmal Atrial Fibrillation
11/22
08/23
NCT05356546: TYRX™ Pocket Health Study

Completed
N/A
36
Europe, Canada, US
Study-required procedures include: tissue collection from device capsule, questionnaire collection, and photo collection
Medtronic Cardiac Rhythm and Heart Failure
Cardiac Disease, Healing Surgical Wounds
07/23
07/23
AVANT GUARD, NCT06096337: Pulsed Field Ablation (PFA) Vs Anti-Arrhythmic Drug (AAD) Therapy As a First Line Treatment for Persistent Atrial Fibrillation

Recruiting
N/A
520
Europe, Canada, US, RoW
FARAPULSE™ Pulsed Field Ablation (PFA) System, Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone
Boston Scientific Corporation
Persistent Atrial Fibrillation
12/25
12/27
NCT04061603: iCLAS™ for Persistent Atrial Fibrillation

Active, not recruiting
N/A
200
Europe, Canada, US
Adagio AF Cryoablation System (iCLAS™)
Adagio Medical
Persistent Atrial Fibrillation
08/23
08/24
NCT04091048: Optimize PRO Study

Active, not recruiting
N/A
800
Europe, Canada, US, RoW
Evolut™ PRO and Evolut™ PRO+ System (Evolut™ FX System for the addendum)
Medtronic Cardiovascular
Symptomatic Aortic Stenosis
12/23
12/24
NCT04600791: BATwire Implant Kit

Active, not recruiting
N/A
93
US
BATwire Implant Kit
CVRx, Inc.
Heart Failure
08/24
07/25
ADVANTAGE AF, NCT05443594: A Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects with Persistent Atrial Fibrillation

Active, not recruiting
N/A
669
Europe, Canada, US
Phase 1: FARAPULSE Ablation System, Phase 2: FARAPULSE Ablation System
Boston Scientific Corporation
Persistent Atrial Fibrillation
03/25
03/25
NCT03970343: Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy

Recruiting
N/A
620
US
OPTIMIZER Smart System
Impulse Dynamics
Heart Failure
03/26
03/26
rēST Study, NCT03884660: Remedē System Therapy Study

Recruiting
N/A
500
Europe, US
remede System
Respicardia, Inc.
Central Sleep Apnea
06/27
06/32
NCT04502316: Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry)

Recruiting
N/A
5000
US
Barostim™ System
CVRx, Inc.
Heart Failure
06/28
06/28
Arshad, Aysha
NCT04502316: Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry)

Recruiting
N/A
5000
US
Barostim™ System
CVRx, Inc.
Heart Failure
06/28
06/28
Musat, Dan
CHANGE AFIB, NCT05130268: Early Dronedarone Versus Usual Care to Improve Outcomes in Persons With Newly Diagnosed Atrial Fibrillation

Completed
4
339
US
Dronedarone, Multaq
American Heart Association, Duke Clinical Research Institute, Sanofi
Atrial Fibrillation
01/24
06/24
NCT04061603: iCLAS™ for Persistent Atrial Fibrillation

Active, not recruiting
N/A
200
Europe, Canada, US
Adagio AF Cryoablation System (iCLAS™)
Adagio Medical
Persistent Atrial Fibrillation
08/23
08/24
DEFINE AFib, NCT04926857: (Atrial Fibrillation)

Completed
N/A
973
US
Non-Interventional
Medtronic Cardiac Rhythm and Heart Failure
Atrial Fibrillation
01/24
01/24
Seifer, Colette
REFINE-ICD, NCT00673842: Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction

Active, not recruiting
3
700
Europe, Canada, US, RoW
Implantable Cardioverter Defibrillator + Usual Care, Implantable Cardioverter Defibrillator, ICD, Usual care, Standard medical therapy alone
University of Calgary, Canadian Institutes of Health Research (CIHR), Alberta Innovation and Science, Medtronic, GE Healthcare, Cardiac Arrhythmia Network of Canada, Accelerating Clinical Trials Consortium
Myocardial Infarction, Sudden Death
12/24
12/24
Suh, Jason
DRAMMATIC, NCT04071457: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Hourglass Jan 2023 - Jun 2023 : From trial for patients with r/r multiple myeloma treated with an IMiD and PI
Recruiting
3
1100
Canada, US
Lenalidomide, CC-5013, Revlimid, Daratumumab/rHuPH20
SWOG Cancer Research Network, National Cancer Institute (NCI), Janssen, LP
Multiple Myeloma
07/29
07/40
Han, Frederick
LESS-VT, NCT03490201: FLExAbility Sensor Enabled Substrate Targeted Ablation for the Reduction of VT Study

Completed
N/A
592
Europe, US, RoW
Market Approved RF Ablation System, FlexAbility SE Ablation Catheter
Abbott Medical Devices
Ventricular Tachycardia
04/24
04/24
NCT04061603: iCLAS™ for Persistent Atrial Fibrillation

Active, not recruiting
N/A
200
Europe, Canada, US
Adagio AF Cryoablation System (iCLAS™)
Adagio Medical
Persistent Atrial Fibrillation
08/23
08/24
Kirshner, Eli
SGNLVA-005, NCT04032704 / 2019-001946-17: A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Terminated
2
205
Europe, US, RoW
ladiratuzumab vedotin, SGN-LIV1A, pembrolizumab, Keytruda
Seagen Inc., Merck Sharp & Dohme LLC
Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma
11/23
11/23
Acclaim-1, NCT04486833: Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

Recruiting
1/2
158
US
quaratusugene ozeplasmid, Reqorsa, osimertinib, Tagrisso, Platinum-Based Chemotherapy, cisplatin, carboplatin
Genprex, Inc.
Carcinoma, Non-Small Cell Lung
03/28
03/29
Acclaim-2, NCT05062980: Quaratusugene Ozeplasmid (Reqorsa) in Combination with Pembrolizumab in Previously Treated Non-Small Lung Cancer

Active, not recruiting
1/2
180
US
quaratusugene ozeplasmid, Reqorsa, pembrolizumab, Keytruda, docetaxel, Taxotere, ramucirumab, Cyramza, Investigator's Treatment of Choice
Genprex, Inc.
Non Small Cell Lung Cancer
12/24
12/25
Altschul, Dorothea
NCT02864953 / 2017-004854-41: Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction

Terminated
3
535
Europe, Canada, Japan, US, RoW
BIIB093, glibenclamide, glibenclamide intravenous (IV), glyburide, CIRARA, Placebo
Remedy Pharmaceuticals, Inc.
Brain Edema, Stroke, Acute
08/23
08/23
CAPTIVA, NCT05047172: Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis

Recruiting
3
1683
US
Ticagrelor + Aspirin, Brilinta, Rivaroxaban + Aspirin, Xarelto, Clopidogrel + Aspirin, Plavix, Risk Factor Management
University of Florida, National Institute of Neurological Disorders and Stroke (NINDS), University of Cincinnati, Medical University of South Carolina, Janssen Scientific Affairs, LLC, AstraZeneca
Intracranial Arteriosclerosis, Stroke
05/28
05/28
Michel, Kimberly
NCT05163548: PerQseal®+ Early Feasibility Study

Completed
N/A
15
US
PerQseal Plus Device, Vascular Closure Device
Vivasure Medical Limited
Percutaneous Large Hole Vascular Closure
07/22
07/22
NCT04818541: PerQseal® Impella Early Feasibility Study

Completed
N/A
19
US
PPCI, Percutaneous PerQseal device closure, Cardiogenic shock
Vivasure Medical Limited
Percutaneous Large Hole Vascular Closure
01/23
03/23
NCT04061603: iCLAS™ for Persistent Atrial Fibrillation

Active, not recruiting
N/A
200
Europe, Canada, US
Adagio AF Cryoablation System (iCLAS™)
Adagio Medical
Persistent Atrial Fibrillation
08/23
08/24
ADVANTAGE AF, NCT05443594: A Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects with Persistent Atrial Fibrillation

Active, not recruiting
N/A
669
Europe, Canada, US
Phase 1: FARAPULSE Ablation System, Phase 2: FARAPULSE Ablation System
Boston Scientific Corporation
Persistent Atrial Fibrillation
03/25
03/25
DEFINE AFib, NCT04926857: (Atrial Fibrillation)

Completed
N/A
973
US
Non-Interventional
Medtronic Cardiac Rhythm and Heart Failure
Atrial Fibrillation
01/24
01/24
Coordinator, Research
CAMPLIFE, NCT06562296: Study Evaluating Several CAMPs in Nonhealing Diabetic Foot and Venous Leg Ulcers

Recruiting
4
292
US
Amnion-Intermediate-Chorion, AIC, Amnion-Chorion-Amnion, ACA, Standard of Care, SOC
Cellution Biologics, SerenaGroup, Inc., LifeCell
Diabetic Foot Ulcer, Venous Leg Ulcer
12/26
07/27
NCT05078827: Therapeutic Equivalence of Fluorouracil Cream, 5% Compared With Fluorouracil 5% Topical Cream of MylanPharmaceuticals Inc., U.S.A in the Treatment of Actinic Keratosis

Completed
3
458
US
Test Product (A): Fluorouracil Cream, 5% topical cream, Experimental, Reference Product (B): Fluorouracil 5% Topical Cream of Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A., Active Comparator, Placebo Product (C): Test vehicle cream for fluorouracil 5% of Encube Ethicals Pvt. Ltd., India, Placebo Comparator
Encube Ethicals Pvt. Ltd., CBCC Global Research
Actinic Keratoses
11/22
12/22
ReMMi-D, NCT05853900: Study of Two Digital Therapeutics for the Prevention of Episodic Migraine

Completed
3
558
US
ReMMi-D Digital Therapeutic
Click Therapeutics, Inc.
Migraine, Episodic Migraine, Headache, Headache, Migraine
05/24
05/24
OPERA-T, NCT05238116 / 2021-004554-32: Safety and Efficacy of PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis ( Study)

Recruiting
3
123
Europe, Canada, US, RoW
PC945, Placebo
Pulmocide Ltd
Refractory IPA
03/26
04/26
NCT06004388: Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C)

Completed
3
110
US
Click Digital Therapeutic
Click Therapeutics, Inc.
Migraine, Episodic Migraine, Headache, Headache, Migraine
05/24
06/24
CONVOKE, NCT05838625: Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia

Recruiting
3
432
US
Digital Therapeutic
Click Therapeutics, Inc., Boehringer Ingelheim
Schizophrenia
06/25
07/25
NCT06067984: An Extension Study of a Second Course of a Digital Therapeutic for the Treatment of Experiential Negative Symptoms of Schizophrenia

Active, not recruiting
3
75
US
Study App
Click Therapeutics, Inc., Boehringer Ingelheim
Schizophrenia, Negative Symptoms in Schizophrenia
04/25
05/25
NCT06365437: A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation

Completed
2
33
Europe
TCD601, Siplizumab, Tacrolimus (TAC), Corticosteroids (CS), Mycophenolate Mofetil (MMF), ATG
ITB-Med LLC
Kidney Transplantation
12/24
12/24
PHYOX8, NCT05001269 / 2021-001083-16: Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function

Recruiting
2
25
Europe, Canada, Japan, US, RoW
nedosiran, DCR-PHXC
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Primary Hyperoxaluria, Primary Hyperoxaluria Type 1, Primary Hyperoxaluria Type 2, Primary Hyperoxaluria Type 3
12/24
12/24
CHASE, NCT05727878: Trial to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With PCED

Recruiting
2
90
US, RoW
KPI-012, KPI-012 Vehicle
Combangio, Inc, Kala Pharmaceuticals, Inc.
Persistent Corneal Epithelial Defect
03/25
10/25
NCT05733546: A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder

Recruiting
2
102
US
Psilocybin, COMP360
COMPASS Pathways
Major Depressive Disorder
10/24
11/24
NCT04270175: Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

Recruiting
2
21
US
Daratumumab SC, Faspro, Pomalidomide, Dexamethasone
Weill Medical College of Cornell University, Janssen Scientific Affairs, LLC
Amyloid, AL Amyloidosis, Refractory AL Amyloidosis
12/25
12/29
NCT04803058: A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE)

Recruiting
2
18
US, RoW
TCD601
ITB-Med LLC
Kidney Transplantation
03/27
03/30
STRIDE, NCT06025110: A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients

Active, not recruiting
2
96
Europe
TCD601, Placebo
ITB-Med LLC
Diabetes Mellitus, Type 1
01/25
01/25
ASCEND, NCT05669001: A Study of TCD601 in de Novo Renal Transplant Recipients

Recruiting
2
90
US
TCD601, siplizumab, belatacept, ATG, antithymocyte globulin, TAC, tacrolimus, MPA, mycophenolic acid, Corticosteroids
ITB-Med LLC
Renal Transplantation
07/25
10/26
NCT04311632: A Dose Escalation Study in de Novo Renal Transplantation

Completed
2
13
US
TCD601, Tacrolimus (TAC), Corticosteroids (CS), Mycophenolate Mofetil (MMF), ATG
ITB-Med LLC
Kidney Transplantation
10/23
10/23
NCT04464980: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

Recruiting
2
2190
US
SL-BUP, sublingual buprenorphine, Suboxone, XR-BUP, extended-release buprenorphine, CAM2038, Brixadi, XR-NTX, extended-release naltrexone, Vivitrol, MM, MMR, MMD
NYU Langone Health, New York State Psychiatric Institute, Columbia University, Harvard Medical School (HMS and HSDM), Mclean Hospital, National Institute on Drug Abuse (NIDA), The Emmes Company, LLC
Opioid Use Disorder (OUD)
07/26
12/26
NCT04803006: A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PANORAMA)

Recruiting
2
18
US
TCD601
ITB-Med LLC
Kidney Transplantation
07/27
07/30
AURORA, NCT06453668: A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients

Active, not recruiting
1
48
Europe
TCD601, siplizumab
ITB-Med LLC
ALS
11/26
11/26
PBL-0405-01, NCT06273852: A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors

Recruiting
1
15
US
PBA-0405, PB004.22.0405.aF
Pure Biologics S.A., Presage Biosciences
Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult, Triple Negative Breast Cancer
03/25
03/25
MST01-AZN-05, NCT06366451: PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, and Sabestomig in HNSCC

Recruiting
1
15
US
Rilvegostomig, AZD2936, Volrustomig, MEDI5752, Sabestomig, AZD7789, Pembrolizumab, Keytruda, MK-3475
Presage Biosciences, AstraZeneca
Head and Neck Squamous Cell Carcinoma
12/24
03/25
OP-1250-003, NCT05508906: Phase 1b Combo w/ Ribociclib, Alpelisib, or Everolimus

Recruiting
1
155
US, RoW
OP-1250, Ribociclib, KISQALI®, Alpelisib, PIQRAY®, Everolimus
Olema Pharmaceuticals, Inc., Novartis
Metastatic Breast Cancer, Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Breast Cancer
05/26
06/26
NCT06798454: Single Ascending Dose Study to Evaluate Safety Tolerability, Pharmacokinetics, and Pharmacodynamics of PVT201 in Healthy Subjects and Patients (PBC/PSC)

Recruiting
1
30
RoW
PVT201, Navacim, Placebo, normal saline, 0.9% NaCl
Parvus Therapeutics, Inc., Avance Clinical Pty Ltd.
Primary Biliary Cholangitis (PBC)
02/25
02/25
NCT04541108: Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

Recruiting
1
15
US
Rilvegostomig, AZD2936, Volrustomig, MEDI5752, Sabestomig, AZD7789, Pembrolizumab, Keytruda, MK-3475
Presage Biosciences, Merck Sharp & Dohme LLC
Solid Tumor
12/31
12/31
NCT06136936: A Study to Evaluate the Overall Effects of Treatment With Abbreviated CT-156 in People With Schizophrenia

Completed
N/A
53
US
CT-156-C-001
Click Therapeutics, Inc., Boehringer Ingelheim
Schizophrenia
01/24
02/24
NCT05222581: Engineering Evaluation of a Breast Pump Device

Recruiting
N/A
20
US
Prototypes of breast shield and Freedom Double Electric Breast Pump
Momtech Inc.
Healthy, Breast Pumping
09/24
11/24
NCT06136923: An Exploratory Study to Evaluate Attention Biases in Adults With Multiple Sclerosis, Breast Cancer, and Lung Cancer

Completed
N/A
194
US
CT-100-D-004-A, CT-100-D-004-B
Click Therapeutics, Inc.
Multiple Sclerosis, Lung Cancer, Breast Cancer
04/24
05/24
LOCAL, NCT04968847: FemaSeed Artificial Insemination Trial

Completed
N/A
314
US
FemaSeed Localized Directional Insemination
Femasys Inc.
Infertility, Male Factor
12/23
04/24
CT-100-D-003, NCT06275659: An Exploratory Study to Evaluate a Digital Intervention to Disrupt Scratching in Atopic Dermatitis and Psoriasis

Active, not recruiting
N/A
120
US
CT-100-004-A, CT-100-004-B
Click Therapeutics, Inc.
Psoriasis, Atopic Dermatitis
02/24
03/24
Lublin, NCT06217081: 3M™ Topical Tissue Adhesive Versus Commercially Available Tissue Adhesive for the Closure of Lacerations and Incisions

Recruiting
N/A
452
US
3M Topical Tissue Adhesive, Histoacryl® Blue Topical Skin Adhesive
Solventum US LLC, United States Department of Defense, The University of Texas Health Science Center at San Antonio, 3M
Trauma-related Wound, Surgical Incision, Surgical Wound, Laceration
11/25
12/25
CoMind EFS, NCT06368648: CoMind Early Feasibility Study

Recruiting
N/A
581
US
CoMind Technologies Limited, Lindus Health
Intracranial Pressure, Intracranial Pressure Changes, Traumatic Brain Injury, Intracerebral Hemorrhage, Encephalitis, Encephalopathy, Hydrocephalus, Stroke, Autoregulation
10/25
10/25
NCT05006404: Autus Valve Pivotal Study

Recruiting
N/A
50
US
Pulmonary Valve Replacement Surgery
Autus Valve Technologies, Inc.
Congenital Heart Disease
08/26
02/36
MASTR, NCT05243966: Myriad™ Augmented Soft Tissue Reconstruction Registry

Recruiting
N/A
800
US
Myriad Matrix™ and Myriad Morcells™
Aroa Biosurgery Limited
Abdominal Wound Dehiscence, Necrotizing Soft Tissue Infection, Lower Extremity Wound, Pilonidal Sinus, Anal Fistula, Hidradenitis Suppurativa, Pressure Injury
01/28
01/29
NCT06770998: A Study of a Novel EEG Neurofeedback System for PTSD Treatment

Not yet recruiting
N/A
250
US
EEG-neurofeedback training, Prism training, amyg-EFP training, active Prism training, Sham training, sham Prism training
Foundation for Atlanta Veterans Education and Research, Inc., GrayMatters Health Ltd., Rochester Institute of Technology, New York University Grossman School of Medicine, Atlanta VA Medical Center, Birmingham VA Health Care System, Ralph H. Johnson VA Medical Center, VA Boston Healthcare System, CTP Inc, BioStats Statistical Consulting Ltd, ShareCRF, United States Department of Defense
Stress Disorders, Post-Traumatic
06/27
08/27
PHONES, NCT04662320: Promoting Healing of Nerves Through Electrical Stimulation

Active, not recruiting
N/A
100
US
Checkpoint BEST System, Brief Electrical Stimulation (BES) Therapy
Checkpoint Surgical Inc., Congressionally Directed Medical Research Programs
Cubital Tunnel Syndrome, Nerve Compression, Nerve Injury, Ulnar Neuropathies
12/25
12/25
FINALE, NCT05977751: Prospective Multi-Center Trial for FemBloc Permanent Birth Control

Recruiting
N/A
573
US
FemBloc
Femasys Inc.
Contraception
12/29
06/31
PHINEST, NCT05884125: Promoting Healing of Injured Nerves With Electrical Stimulation Therapy

Recruiting
N/A
60
US
Checkpoint BEST System, Brief Electrical Stimulation (BES) Therapy
Checkpoint Surgical Inc., Congressionally Directed Medical Research Programs
Nerve Injury, Peripheral Nerve Injuries, Peripheral Nerve Injury Upper Limb, Nerve Palsy
06/27
06/27
NCT05678530: Observational, Non-Interventional Study Supporting Validation of VO2Max Estimation Methods Using Results in Patients Receiving Standard of Care Cardiopulmonary Exercise Tests (CPET)

Recruiting
N/A
400
Canada, US
Prolaio
Cardiopulmonary
06/25
06/25
Teplinsky, Eleonora
NCT05161195 / 2021-005184-42: Roll-over Study to Allow Continued Access to Ribociclib

Recruiting
4
137
Europe, Japan, US, RoW
Ribociclib, Letrozole, Anastrozole, Goserelin, Tamoxifen, Fulvestrant
Novartis Pharmaceuticals, Novartis Pharma AG
Metastatic Breast Cancer
01/28
02/28
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
FLORA-4, NCT04498117 / 2020-002270-26: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Active, not recruiting
3
615
Europe, Canada, US, RoW
Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo
CanariaBio Inc., Gynecologic Oncology Group, Iqvia Pty Ltd
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms
09/25
08/27
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer

Recruiting
3
418
Europe, Canada, US, RoW
Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab
AbbVie, GOG Foundation
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
03/27
04/29
DENALI, NCT05128825: A Study of ZN-c3 in Subjects With High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Active, not recruiting
2
102
Europe, US, RoW
ZN-c3, azenosertib
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
04/25
10/25
Abbate, Kariann
PROACTIVE-HF, NCT04089059: IDE Trial Heart Failure NYHA Class III

Active, not recruiting
N/A
457
Europe, US
Cordella™ Pulmonary Artery Sensor System
Endotronix, Inc.
Heart Failure NYHA Class III
04/28
04/28
Sayles, Kathleen
NCT05693090: Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer

Withdrawn
1
50
US
Tipifarnib, Osimertinib
Kura Oncology, Inc.
NSCLC
07/27
07/27
Wilson, Sean R
CLASP IID, NCT03706833: Edwards PASCAL /IIF Pivotal Clinical Trial

Recruiting
N/A
1247
Europe, Canada, US
Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System
Edwards Lifesciences
Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
01/25
04/30
Bowden, Nancy
AVANT GUARD, NCT06096337: Pulsed Field Ablation (PFA) Vs Anti-Arrhythmic Drug (AAD) Therapy As a First Line Treatment for Persistent Atrial Fibrillation

Recruiting
N/A
520
Europe, Canada, US, RoW
FARAPULSE™ Pulsed Field Ablation (PFA) System, Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone
Boston Scientific Corporation
Persistent Atrial Fibrillation
12/25
12/27
Mendoza, Eliany
NCT03970343: Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy

Recruiting
N/A
620
US
OPTIMIZER Smart System
Impulse Dynamics
Heart Failure
03/26
03/26
Gupta, Himanshu
NCT06018194: ELUCIDATE FFRct Study

Recruiting
N/A
350
US
ElucidVivo
Elucid Bioimaging Inc., Lundquist Institute at Harbor-UCLA Medical Center
Coronary Artery Disease
07/24
07/24
TRANSFORM, NCT06112418: A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events

Recruiting
N/A
7500
US
The Cleerly CAD Staging System
Cleerly, Inc., CPC Clinical Research
Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome
03/29
03/29
Tedeschi, Lauren
NCT05653336: PerQseal® Clinical Study

Active, not recruiting
N/A
149
Europe, US
PerQseal® Closure Device System
Vivasure Medical Limited
Percutaneous Large Hole Vascular Closure
12/24
06/25
NCT04600791: BATwire Implant Kit

Active, not recruiting
N/A
93
US
BATwire Implant Kit
CVRx, Inc.
Heart Failure
08/24
07/25
 

Download Options